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Abstract
Background and Aims: Nonalcoholic fatty liver disease (NALFD) is a leading cause of liver disease. Weight loss improves
clinical features of NAFLD; however, maintenance of weight loss outside of investigational protocols is poor. The goals of
this study were to characterize patterns and clinical predictors of long-term weight loss in ambulatory patients with NAFLD.
Methods: We retrospectively reviewed 924 non-cirrhotic patients with NAFLD presenting to a liver clinic from May 1st 2007
to April 30th 2013. Overweight and obese patients were counseled on lifestyle modifications for weight loss as per USPSTF
guidelines. The primary outcome was percent weight change between the first and last recorded visits: % weight change =
(weightinitial – weightfinal)/(weightinitial). Baseline BMI and percent BMI change were secondary measures. Predictors of
weight loss were determined using logistic regression.
Results: The mean baseline BMI was 33.366.6 kg/m2, and the mean follow-up duration was 17.3617.6 months. Most
patients with NAFLD were in either overweight (26.1%) or class I obesity (30.5%) categories at baseline, while the prevalence
of underweight and class III obesity was lower (0.2% and 15.4%, respectively). Overall, there was no change in mean weight
or BMI during the follow-up period, and only 183 patients (19.8%) lost at least 5% body weight during the follow up period.
Independent predictors of weight loss included number of clinic visits and baseline BMI, and patients with higher baseline
BMI required more clinic visits to lose weight.
Conclusions: Weight loss is largely unsuccessful in NAFLD patients in the ambulatory care setting. Frequent clinical
encounters are associated with weight reduction, especially among individuals with high baseline BMI. Future studies are
required to define effective weight loss strategies in NAFLD patients.
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Introduction
With the rise of obesity and the metabolic syndrome,
nonalcoholic fatty liver disease (NAFLD) has become a major risk
factor for both cardiovascular disease and cirrhosis [1]. By
conservative estimates, approximately 20–30% of adults in
developed nations are affected. In the United States, population
based studies have reported a prevalence of 10–46%, while the
prevalence of biopsy-proven nonalcoholic steatohepatitis (NASH)
ranges from 3–5% [2–4]. NAFLD is also an emerging health
concern in the developing world; as up to 30% of certain Asian
populations exhibit significant steatosis [5]. Although age,
hypertension, gender, diet and genetic polymorphisms have been
implicated as predictors for the development of NAFLD, the
strongest risk factors are insulin resistance and obesity. In addition,
it has been suggested that NAFLD rates rise with increasing levels
of obesity [2,6].
Multiple trials have demonstrated that weight loss reduces
intrahepatic fat content and improves serum aminotransferases
[7–11]. Furthermore, increased weight loss is associated with
greater improvement in histologic steatosis, hepatocyte ballooning,
and lobular inflammation [8,10]. Based on these findings, practice
guidelines from the American Association for the Study of Liver
Diseases recommend weight loss as a treatment for NAFLD [12].
The optimal approach to weight loss, however, remains unclear, as
multiple interventions, including dietary modification, physical
activity, medications, and bariatric surgery are currently used.
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Additionally, maintenance of weight loss outside of investigational
protocols remains challenging. In a pooled follow-up analysis of
three large weight loss trials, 28% of patients maintained weight
loss in the second year after intervention, while only 23% did not
gain weight in the third year [13]. These findings and others
highlight concerns regarding effective implementation of investi-
gational weight loss protocols in real-world practice settings.
Currently, American Association for the Study of Liver Diseases
(AASLD) guidelines suggest that weight loss of 3–5% may improve
hepatic steatosis, while weight loss of 10% or more may be
required to improve necroinflammation [12]. The effectiveness of
these weight loss recommendations in NAFLD patients outside of
clinical trials is not known. Therefore, the goal of this analysis was
to characterize patterns of long-term weight loss in a large,
ambulatory cohort of patients with NAFLD. In addition, we
sought to determine clinical predictors of successful weight loss in
this population.
Methods
Ethics statement
The University of Pittsburgh institutional Review Board
approved this retrospective cohort study with a waiver of consent
(approval number PRO12030073). Subjects with NAFLD were
identified by ICD-9 codes using the University of Pittsburgh
Center for Liver Diseases (CLD) Research Registry, which consists
of ambulatory patients with chronic liver diseases presenting to the
CLD for long-term care. All patient records were de-identified
prior to analysis.
Study design and participants
A flow diagram of the population selection strategy is depicted
in Figure S1. Patients initially encountered in the CLD from
May 1st 2007 to April 30th 2013 were included in the study.
Subjects 18 years of age or older with NAFLD were identified
from the registry using ICD-9-CM code 571.8 (‘‘other chronic
nonalcoholic liver disease’’), and those with two or more
subsequent visits were included in the analysis. Individuals were
excluded if documented height or weight measurements were
Table 1. Demographics and clinical characteristics of the study population (N= 924).
VARIABLE
Age (years)* 53.6612.7
Duration of follow up (months)* 11(3.5,25.5)
Number of clinic visits* 3.862.5
Average number of visits per year* 1.760.6
Initial BMI (kg/m2)* 33.366.6
Final BMI (kg/m2)* 3366.6
Initial Weight (kg)* 95.1620.8
Final Weight (kg)* 94.4620.7
Male gender{ 372 (40.3%)
Race{
White 870 (94.2%)
African-American 27 (2.9%)
Others 27 (2.9%)
Hypertension{ 191 (20.7%)
Diabetes mellitus{ 163 (17.6%)
Psychiatric comorbidity{ 92 (10%)
Hyperlipidemia{ 253 (27.4%)
Death{ 6 (0.7%)
Values presented as *mean 6 SD or {N (%) or median(ICR).
doi:10.1371/journal.pone.0111808.t001
Figure 1. Initial body mass index (BMI) distribution of 924 non-
cirrhotic NAFLD patients. Baseline BMI was stratified using the
following definitions: underweight (,18.5 kg/m2), normal weight (18.5–
24.99 kg/m2), overweight (25.0–29.99 kg/m2), class I obesity (30.0–
34.99 kg/m2), class II obesity (35.0–39.99 kg/m2), and class III obesity
($40 kg/m2).
doi:10.1371/journal.pone.0111808.g001
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missing at initial or subsequent encounters. Patients with other
liver diseases (determined by their ICD9 codes) including viral
hepatitis, autoimmune hepatitis, hemochromatosis and alpha-one
antitrypsin deficiency were also removed. Other exclusion criteria
included human immunodeficiency virus (HIV), celiac disease,
prior solid organ transplant, hepatocellular carcinoma, prior
gastrointestinal bypass surgery and ongoing ethanol use. Initially,
patients with cirrhosis were excluded, as previous studies have
demonstrated that total body weight does not accurately reflect
body composition in this population [14,15]. In particular,
cirrhotic subjects with ascites are prone to iatrogenic weight loss
due to diuretic use or large volume paracentesis. A previously
validated combination of ICD-9 codes was used to identify
cirrhotic patients among the NAFLD cohort [16], and these were
removed from the primary analysis. We then also assessed the
primary outcome (percentage weight change) after including
cirrhotic subjects. Patients with two or more clinic visits, with
documented heights and weights were included for analysis. We
used the same exclusion criteria used for pure NAFLD patients,
such as viral hepatitis, autoimmune hepatitis, alpha-one antitryp-
sin deficiency, human immunodeficiency virus (HIV), celiac
disease, prior solid organ transplant, hepatocellular carcinoma,
prior gastrointestinal bypass surgery and ongoing ethanol use. The
primary outcome, percent weight change was assessed exactly as
for noncirrhotic NAFLD patients.
Subjects were followed from the first clinical encounter on or
after May 1st 2007 until their final clinical encounter on or before
April 30th, 2013. The primary outcome was percent weight
change, which was measured between the first and last recorded
visits: % weight change = (weightinitial – weightfinal)/(weightinitial).
Weight change was then classified into 5 categories: weight gain .
10%, weight gain 5–10%, weight change ,5%, weight loss 5–
10%, and weight loss .10%. Secondary outcomes included
absolute and percent change in BMI (absolute BMI change =
BMIintial – BMIfinal; % BMI change = (BMIinitial – BMIfinal)/
BMIinitial).
Clinical and demographic variables
All patient encounters took place in a single climate controlled,
indoor clinic, and all subject wore light clothing without shoes for
measurements. Patient age and gender were recorded; patient race
was self-reported. Three weight measurements were obtained by
trained medical assistants using a calibrated beam balance scale,
and two consistent results were recorded. Among these, one was
chosen as the final weight; and this result was recorded to the
nearest 0.1 kg. Height was measured to the nearest centimeter
using a stadiometer positioned at the top of each patient’s head.
Body mass index (BMI) was determined at the initial and final
visits using the following formula: BMI = mass (in kg)/(height in
m2). Baseline BMI was stratified according to World Health
Organization (WHO) definitions of obesity as follows [17]:
underweight (,18.5 kg/m2), normal weight (18.5–24.99 kg/m2),
overweight (25.0–29.99 kg/m2), class I obesity (30.0–34.99 kg/
m2), class II obesity (35.0–39.99 kg/m2), and class III obesity
($40 kg/m2).
The presence of comorbid conditions associated with obesity
was abstracted from the Registry database using associated ICD-9
codes. These included diabetes mellitus (DM), hypertension,
hyperlipidemia, gastrointestinal reflux disease (GERD) and psy-
chiatric conditions such as depression and anxiety. The follow-up
interval was calculated as follows: [(date of last visit) – (date of first
visit)]/30 and expressed in units of months. Values were rounded
to one decimal place. The number of visits per years was defined
as follows: number of total visits (n)/follow-up duration (years).
During each clinic visit, patients were counseled by their
physician or advanced practice provider regarding the importance
of weight loss for reducing liver fat and liver inflammation.
Providers provided counseling to their patients during the office
visit about the health benefits of weight loss and lifestyle changes as
outlined in US Preventive Services Task Force (USPSTF)
guidelines [18,19]. Since the purpose of this study was to
determine the effectiveness of routine medical care outside of a
clinical trial to encourage weight loss in patients with NAFLD, the
providers in the practice were not required to adhere to
standardized recommendations for lifestyle modifications.
Statistical analysis
Statistical analysis was performed with Stata version 12
(StataCorp, College Station, TX). Continuous variables are
presented as mean 6 standard deviation (S.D.) or median
(interquartile range [IQR]) for parametric and non-parametric
data respectively, and categorical variables are presented as
absolute frequencies and percentages. Normality of the continuous
variables was assessed visually with histograms. Comparisons
between groups were performed with the x2 test for categorical
variables (or Fischer’s exact test when expected values were #5),
while the student’s t test was used for continuous variables. Logistic
regression analysis was used to determine predictors of weight loss
of at least 5%, which was coded as a dichotomous variable.
Individuals who achieved weight loss of 5% or more were coded
‘‘1’’, while those who did noted were coded as ‘‘0’’. Patient
characteristics with p,0.25 in the univariate analysis were then
included in multivariable model. Collinearity was assessed by
variance inflation factor calculation and pairwise correlation;
Akike Information Criterion analysis was then used to compare
models excluding each collinear variable separately to determine
which to exclude from the final multivariable model. A p value
(two-tailed) less than or equal to 0.05 was considered statistically
significant.
As physicians may schedule frequent return clinic visits for
patients with higher BMI, an interaction term between number of
Figure 2. Percent change in body weight at the end of the
study period relative to the initial weight. Patients with final body
weight within 5% of their initial weight were included in the ‘‘No
change’’ group. N= 924 for the entire cohort.
doi:10.1371/journal.pone.0111808.g002
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clinic visits and baseline BMI was included in the multivariable
logistic regression model, and results were interpreted using
adjusted marginal effects methods [20].
Results
Clinical and demographic features of patients
Clinical and demographic characteristics are summarized in
Table 1. The study cohort included 924 subjects (Table S1). The
population was predominantly Caucasian (n= 870, 94.2%) and
female (n = 552, 59.7%). The median duration of follow-up was11
months (IQR 3.5–22.5 months), and on average, 3.862.5 visits
occurred during that interval. Overall, the cohort was obese, and
the mean weight of the patients at the time of the first visit was not
significantly different than the mean weight of the patients at the
time of last clinic visit. Similarly, the mean BMI of the patient
population at the time of the first visit was not significant different
than the mean BMI of the patients at the time of last clinic visit.
Comorbidities associated with obesity such as hypertension,
diabetes mellitus, and GERD were commonly encountered in
the study population, and 10% of patients suffered from
psychiatric illness. Six individuals (0.7%) died during the study.
The baseline BMI profile is depicted in Figure 1, and a bell-
shaped distribution was observed. The majority of patients with
NAFLD had either overweight (26.1%) or class I obesity (30.5%),
while the prevalence of underweight and class III obesity was
significantly lower.
Patterns of Weight Change and Predictors of Weight Loss
in NAFLD
We characterized patterns of weight change in our NAFLD
cohort, and these findings are depicted in Figure 2. The majority
of patients experienced minimal weight change of less than 5%
during the study period (n= 610, 66%); however, weight loss of at
least 5% was more common than weight gain of at least 5% in this
cohort (183 versus 131 patients). NAFLD can lead to the
development of liver cirrhosis and many patients have established
cirrhosis when they are diagnosed. Our initial analysis was limited
to NAFLD patients without established cirrhosis. Therefore, we
next examined weight loss in an expanded cohort consisting of
Table 2. Univariate logistic regression for predictors of weight loss (N= 924).
Variable OR 95% CI P value
Duration of follow up 1.01 1.004,1.02 0.003
Age 1.00 0.99,1.02 0.70
Average number of visits per year 1.19 0.90,1.56 0.22
Number of distinct years seen in clinic
1 year Baseline ,0.001
2 year 2.08 1.33,3.24
3 years 1.93 1.11,3.38
$4 years 2.70 1.62,4.49
Total Number of Visits
2 visits Baseline ,0.001
3 visits 3.26 2.03,5.24
4 visits 3.74 2.23,6.30
$5 visits 3.29 1.89,5.75
Diabetes mellitus 1.29 0.86,1.94 0.22
Hyperlipidemia 1.34 0.94,1.90 0.1
Initial BMI*Total Number of Clinic Visits 0.045
2 visits Baseline
3 visits 1.055 .99,1.14
4 visits 1.063 0.98.1.15
5 visits 1.11 1.02,1.19
Gender
Male Baseline 0.34
Female 1.18 0.84,1.64
Psychiatric Comorbidity 0.7 0.39,1.27 0.25
Hypertension 0.93 0.62,1.39 0.71
Initial BMI 1.03 1.02,1.06 0.001
Race
Caucasian Baseline 0.75
African-American 0.7 0.24,2.05
Other 1.15 0.46,2.89
Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index.
doi:10.1371/journal.pone.0111808.t002
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1413 NAFLD patients with and without cirrhosis. The results were
similar to that in noncirrhotic NAFLD patients, with the majority
of individuals experiencing weight change of less than 5% (data
not shown).
Next, logistic regression methods were used to determine
predictors of weight loss of 5% or more (Tables 2 and 3). While
duration of follow-up was identified as a predictor of weight loss in
the univariate analysis, it was not significantly associated with
weight loss in the multivariate model. The main effects of initial
BMI and the total number of clinic visits in the model cannot be
interpreted in the presence of a significant interaction (p=0.05).
The odds ratio of weight loss of 5% or more for one unit increase
in initial BMI at two, three, four and five (or more) clinic visits was
0.98 (p=0.68), 1.04 (p=0.11), 1.05 (p=0.09) and 1.10 (p,0.001)
respectively. This demonstrates that initial BMI was significantly
associated with weight loss of 5% or more only for those patients
with five or more clinic visits; among this subset, increased BMI is
associated with increased odds of weight loss of 5% or more.
To increase comprehension/applicability of the model, we also
assessed odds ratio of weight loss of 5% or more for a patient with
average BMI (33.3 kg/m2) for three 3.33 (p,0.001), four 3.78 (p,
0.001) and five (or more) 3.08 (p=0.004) clinic visits compared to
those with two clinic visits respectively.
The cumulative effect of initial BMI and clinic visits on weight
loss probability is depicted in Figure 3. In patients with at least
three clinic visits, the probability of weight loss of 5% or more
increased proportionally with rising baseline BMI, while among
those with two encounters, the probability of weight loss decreased
with higher baseline BMI.
Discussion
Four novel observations were made in this study, which
characterizes patterns of weight change in a large ambulatory
cohort with NAFLD. First, most non-cirrhotic patients with
NAFLD exhibited either overweight (BMI 25.0–29.99 kg/m2) or
Class I obesity (BMI 30.00–34.99 kg/m2), while the prevalence of
Class II or III obesity was lower. Second, over 80% of patients
failed to lose at least 5% body weight during the follow-up period,
and this finding was reproduced in a larger cohort of both cirrhotic
and non-cirrhotic NAFLD patients. Third, we identified baseline
Table 3. Multivariate logistic regression for predictors of weight loss (N = 924).
Variable Model With Interaction Model Without Interaction
AOR 95% CI P value AOR 95% CI P value
Total number of visits
2 visits Baseline 0.29 Baseline ,0.001
3 visits 0.55 0.04,7.01 3.43 2.03,5.79
4 visits 0.49 0.03,7.57 3.88 2.09,7.19
$5 visits 0.09 0.01,1.21 3.37 1.58,7.16
Duration of follow up 0.99 0.97,1.02 0.66 0.99 0.97,1.01 0.6
Initial BMI 0.99 0.94,1.04 ,0.001 1.05 1.02,1.07 0.004
Number of distinct years seen in clinic
1 year Baseline 0.28 Baseline 0.27
2 year 1.23 0.73,2.08 1.32 0.78,2.23
3 years 0.81 0.37,1.78 0.89 0.41,1.94
$4 years 1.38 0.45,4.19 1.49 0.49,4.51
Hyperlipidemia 1.39 0.93,2.06 0.45 1.33 0.89,1.97 0.16
Initial BMI*Total Number of Clinic Visits
2 visits Baseline 0.04
3 visits 1.06 0.98,1.14
4 visits 1.06 0.98,1.15
5 visits 1.11 1.03,1.19
Abbreviations: AOR, Adjusted odds ratio; CI, confidence interval; BMI, body mass index.
doi:10.1371/journal.pone.0111808.t003
Figure 3. Predicted probability of weight loss (.5% of initial
weight) based on number of clinic visits and BMI. Patients were
stratified based on their initial BMI (used as a continuous variable) and
number of clinic visits. N = 924 total patients; 2 visits: 354; 3 visits: 202; 4
visits: 130; and 5 or more visits: 238. P,0.001 for 2 visits versus 3, P,
0.05 for 2 visits versus 4, and P= NS for 2 versus 5 or more visits. P = NS
for 3 versus 4, or 5 or more visits.
doi:10.1371/journal.pone.0111808.g003
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BMI and number of clinical visits as independent predictors of
weight loss. Last, but not the least, weight loss in real life setting in
outpatient clinics is largely unsuccessful.
Obesity is a primary risk factor for the development of NAFLD
[2,12], and the prevalence of NAFLD rises with increasing BMI
and is associated with development of cirrhosis [21,22]. In the
current study, however, the majority of patients had either
overweight or class I obesity, while fewer patients exhibited more
advanced obesity. Weight loss is an effective treatment for
NAFLD, as trials of both lifestyle modification and pharmacologic
weight reduction have demonstrated histologic improvements in
both steatosis and inflammation with 5% or more weight loss
[8,10].
In this study, we found that baseline BMI and number of clinic
visits were independently associated with significant weight loss,
while duration of follow-up was not a significant predictor. The
effect of baseline BMI on weight loss may be related to altered
energy expenditure. As increased baseline BMI is associated with
heightened basal metabolic rate, weight loss programs utilizing
caloric deficits may preferentially enhance early weight loss in this
population [23,24]. Although it is well-documented that a
combination of educational, behavioral and motivational strategies
help patients achieve healthy weight loss [25,26], maintenance of
weight remains challenging. Nonetheless, there is evidence that
frequent clinical encounters preserve weight loss. In a trial
comparing face-to-face visits, quarterly newsletters, and Internet-
based interactions for maintenance of weight loss, subjects who
underwent clinical encounters gained less weight than those in
nonpersonal intervention groups [27]. Comparable results were
observed in a subsequent analysis comparing personal encounters
to non-human interventions for weight loss maintenance [28].
Consistent with these findings, we observed that patients with
three or more clinical visits had a significantly increased
probability of losing weight. This effect may be related to
increased patient exposure to counseling regarding weight loss
with more frequent clinical visits, and future studies are planned to
test this hypothesis.
To assess the relationship between initial BMI and number of
clinic visits on weight loss, we modified the original multivariable
regression model to include an interaction between these
predictors. Two important findings were noted. First, weight loss
probability increased proportionally with baseline BMI in patients
with three or more visits, while it decreased inversely with BMI in
those with two visits, suggesting that two visits may be insufficient
for weight loss in severely obese individuals. Second, the
probability of weight loss was higher in patients with three or
more visits compared to those with two encounters. The
advantage of additional clinic visits, however, was dependent on
baseline BMI, as more encounters were required to confer a
benefit in patients with higher baseline BMI. Together, these
findings underscore the importance of frequent clinical interac-
tions across multiple BMI levels.
Our results have clinical implications for practitioners taking
care of patients with nonalcoholic fatty liver disease. There is an
urgent need to define practical and effective interventions to
promote weight loss in this population. Most encounters in our
cohort were one-to-one interactions between patients and
providers, which our results suggest are largely unsuccessful.
Thus, an alternate multidisciplinary approach, which includes
evaluation and advice provided by dieticians, exercise physiolo-
gists, and, perhaps, psychologist, is likely to be beneficial, although
a major barrier to this multidisciplinary approach in the US is lack
of insurance coverage for these services.
Our results suggest that individual providers can have an impact
on the achievement of weight loss in their patients through regular
and frequent counseling during face-to-face encounters. It is also
important to emphasize that even modest weight loss can have
significant long-lasting effects on improvement in liver steatosis,
even if patients later regain weight, and that exercise is a promising
intervention for NAFLD even in the absence of weight loss [29–
31].
A few limitations of this study should be noted. First, this is a
retrospective analysis. However, data for a large number of
patients was accumulated for an extended duration, and by
examining an ambulatory cohort, we were able to capture features
of weight loss in a real-world clinical practice. Second, weight loss
interventions were limited to brief counseling according to
USPSTF guidelines [18,19], and it would useful to study particular
techniques utilized by those who lost significant weight. Moreover,
as only initial and final weight data were available for anaylsis,
temporal fluctuations in weight were not recorded. Next,
information about food intake and physical activity were not
obtained, and both of these factors may influence intrahepatic fat
content independent of changes in body weight [30,31]. Finally,
there was significant variability in follow-up intervals, but this was
accounted for in multivariate logistic regression models. Neither
number of visits per year nor follow-up duration signficantly
influenced the odds of weight loss.
In conclusion, our findings demonstrate that among patients
with NAFLD, weight loss is largely unsuccessful in real world
clinical settings. All the same, there appears to be a beneficial
impact from clinician interactions, as increased number of clinical
encounters is associated with enhanced probability of weight
reduction. Future studies are required to target successful weight
loss strategies to high-risk populations.
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